Core Insights - The company reported a net sales increase of 16% in H1 2025 compared to H1 2024, reaching DKK 154.9 billion, with an operating profit growth of 25% to DKK 72.2 billion [2][4] - Despite strong sales growth, the company has lowered its full-year outlook due to reduced growth expectations for GLP-1 treatments in the second half of 2025 [3][4] - The company is focusing on enhancing commercial execution and ensuring cost efficiencies while continuing to invest in future growth opportunities [3][4] Financial Performance - Net sales for H1 2025 were DKK 154,944 million, up from DKK 133,409 million in H1 2024, representing a 16% increase [2] - Operating profit rose to DKK 72,240 million, a 25% increase from DKK 57,780 million in the previous year [2] - Net profit increased by 22% to DKK 55,537 million from DKK 45,457 million [2] Sales Breakdown - Sales in US Operations increased by 16% in Danish kroner, positively impacted by gross-to-net sales adjustments, including a DKK 3 billion adjustment in Q2 2025 [4] - Sales in International Operations also grew by 16% in Danish kroner [4] - Sales within Diabetes and Obesity care rose by 16% to DKK 145.4 billion, driven by a 56% increase in Obesity care sales to DKK 38.8 billion [4] Research and Development - The company plans to advance subcutaneous and oral amycretin into phase 3 development for weight management [4] - REDEFINE 11 has been initiated to further investigate the efficacy and safety of CagriSema, and a higher dose of semaglutide has been submitted to EU regulatory authorities [4] Outlook - The sales growth outlook for 2025 is now expected to be 8-14% at constant exchange rates, with operating profit growth expected at 10-16% [4] - The lowered outlook is attributed to slower-than-expected market expansion and competition in the GLP-1 treatment space [4] Leadership Changes - Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as president and CEO, effective 7 August 2025 [4] - The company will consolidate its research and development areas under Martin Holst Lange's leadership [4]

Nasdaq CopenhagenEuronext DublinLondon Stock Exchange Other stakeholders Date: 6 August 2025 Upward adjustment of expectations for 2025 Ringkjøbing Landbobank is upwardly adjusting its expectations for net profit for 2025. The expectations for net profit for the year are upwardly adjusted from the DKK 1,800 – 2,200 million range to the DKK 2,000 – 2,350 million range. The upward adjustment is based on a continued good credit quality and a loss and impairment level that has developed better than originally ...

Core Viewpoint - ABN AMRO has announced a share buyback programme with a total value of EUR 250 million aimed at reducing its share capital [1][2]. Group 1: Share Buyback Programme Details - The share buyback programme will commence on 7 August 2025 and is expected to conclude by December 2025 [2]. - The maximum number of shares to be repurchased will not exceed 10% of the issued shares, as authorized by the general meeting of shareholders on 23 April 2025 [1][3]. - The capital required for the buyback has been reserved and is excluded from the CET1 ratio of 14.8% reported at the end of Q2 2025 [2]. Group 2: Regulatory and Execution Aspects - The European Central Bank (ECB) has approved the share buyback programme, which will comply with the Market Abuse Regulation [3]. - NLFI will participate in the buyback in proportion to its current stake of 30.5% through off-market transactions [3]. - ABN AMRO has established a non-discretionary arrangement with a financial intermediary to conduct the buyback in the open market [4]. Group 3: Communication and Reporting - ABN AMRO will provide weekly updates on the progress of the share buyback programme through press releases and on its Investor Relations website [4].

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL Reference is made to the stock exchange announcement made by Prosafe SE ("Prosafe" or the "Company") on 23 July 2025 regarding commencement of the subscription period (the "Subscription Peri ...

Core Insights - Wix.com Ltd. reported strong financial results for Q2 2025, with total revenue of $489.9 million, representing a 12% year-over-year increase [6][8] - The company is experiencing significant growth in new cohort bookings, which grew 14% year-over-year, with early Q3 bookings showing over 20% growth year-over-year [5][8] - The acquisition of Base44 is expected to significantly enhance Wix's total addressable market, particularly in application development, with projected annual recurring revenue (ARR) growth from a few million to $40-50 million by the end of 2025 [3][5] Financial Performance - Total revenue for Q2 2025 was $489.9 million, up 12% year-over-year, with Creative Subscriptions revenue at $345.5 million (up 11% year-over-year) and Business Solutions revenue at $144.5 million (up 17% year-over-year) [6][8] - Non-GAAP net income for Q2 2025 was $136.2 million, or $2.44 per basic share, compared to $1.03 per basic share for GAAP net income [10][9] - Free cash flow for Q2 2025 was $147.7 million, with total bookings reaching $509.9 million, an 11% increase year-over-year [6][10] Growth Outlook - The company raised its full-year bookings outlook to $2,040 - $2,075 million, reflecting an expected growth of 11-13% year-over-year, driven by strong new cohort performance and contributions from Base44 [8][9] - Wix anticipates total revenue for Q3 2025 to be between $498 - $504 million, representing a 12-13% year-over-year increase [9] - The company expects to generate free cash flow of $595 - $610 million in 2025, which would be approximately 30-31% of revenue [12] Strategic Initiatives - The ongoing demand for AI-powered online creation is driving Wix's growth, with the company focusing on expanding into new markets enabled by AI technologies [2][3] - The acquisition of Base44 is seen as a strategic move to enhance Wix's capabilities in application development and to attract new audiences [3][5] - Wix's business fundamentals are improving, with better conversion rates across key markets and increased monetization from recently launched AI tools [5][8]

Core Insights - Sanofi has completed the acquisition of Vigil Neuroscience, enhancing its early-stage pipeline in neurology with VG-3927, a novel oral TREM2 agonist for Alzheimer's disease [1][2] - The acquisition includes Vigil's preclinical pipeline, further bolstering Sanofi's research in neurodegenerative diseases [1] - Sanofi's financial guidance for 2025 remains unaffected by this acquisition [2] Financial Details - Sanofi acquired all outstanding common shares of Vigil for $8 per share, totaling an equity value of approximately $470 million on a fully diluted basis [6] - Vigil's shareholders will receive a contingent value right (CVR) entitling them to a deferred cash payment of $2 upon the first commercial sale of VG-3927 [6] Strategic Context - In June 2024, Sanofi made a $40 million strategic investment in Vigil, which included exclusive rights for VG-3927 [2] - The acquisition does not include Vigil's second clinical program, VGL101 [2]

Company Overview - VGP NV is a pan-European owner, manager, and developer of high-quality logistics and semi-industrial properties, as well as a provider of renewable energy solutions [3] - The company operates with around 380 full-time employees across 18 European countries, utilizing a fully integrated business model [3] - VGP was founded in 1998 as a family-owned Belgian property developer in the Czech Republic [3] Financial Highlights - As of December 2024, VGP's gross asset value, including 100% joint ventures, amounted to €7.8 billion [3] - The company's net asset value (EPRA NTA) was reported at €2.4 billion [3] Upcoming Events - VGP will review its financial results for the first half of 2025 on 21 August 2025 at 10:30 a.m. (CET) [5] - The financial results are scheduled to be released at approximately 7:00 a.m. (CET) on the same date, with presentation slides available on their investor website [1][4]

Ad hoc announcement pursuant to Art. 53 LRBaar, Switzerland, August 6, 2025First half of 2025 at a glance: Net revenue of CHF 140.0 million (H1/2024: CHF 142.1 million), reflecting a slight increase of 0.2% at constant currencies and a decrease of 1.5% at actual currencies.Incoming orders amounted to CHF 156.6 million (H1/2024: CHF 166.1 million), reflecting a decrease of 4.2% at constant currencies and a decrease of 5.7% at actual currencies. EBITDA increased by CHF 1.6 million to CHF 12.1 million (H1/2024 ...

ABN AMRO posts net profit of EUR 606 million in Q2 2025 6 August 2025 Key messages Solid financial performance: Net profit EUR 606 million and return on equity 9.4% Continued growth: Mortgage portfolio expanded by EUR 1.8 billion and client assets by EUR 8.6 billion Stable income: Limited impact from geopolitical uncertaintyCost discipline: Underlying costs slightly lower than last quarter, reflecting decline in external FTEs Sound credit quality: EUR 6 million in net impairment releases, reflecting limited ...

Core Insights - Aura Minerals Inc. reported record-high Adjusted EBITDA of US$106 million in Q2 2025, driven by increased production and higher gold prices [2][3] - The company achieved significant milestones, including the publication of the Preliminary Economic Assessment for the Era Dorada project and the signing of a purchase agreement for the MSG mine [2][5] - Aura approved a quarterly dividend payment, yielding a 7.4% return to shareholders over the last twelve months [2] Financial Performance - Total production in Q2 2025 reached 64,033 gold equivalent ounces (GEO), a 7% increase from Q1 2025 and consistent with Q2 2024 [3][14] - Net revenue for Q2 2025 was US$190.4 million, an 18% increase from Q1 2025 and a 42% increase year-over-year [3][19] - Gross profit for Q2 2025 was US$103.9 million, with a gross margin of 55%, compared to 48% in Q1 2025 [3][22] Cost Metrics - Cash cost per GEO in Q2 2025 was US$1,146, slightly up from US$1,149 in Q1 2025, and a 6% increase from Q2 2024 [20][21] - All-in sustaining cost (AISC) for Q2 2025 was US$1,449 per GEO, a 1% decrease from Q1 2025 and a 9% increase year-over-year [20][21] Operational Highlights - The Borborema project commenced operations, producing 2,577 GEO in Q2 2025, and is expected to declare commercial production by the end of Q3 2025 [6][14] - The MSG acquisition is expected to close by Q3 2025, enhancing Aura's operational footprint in Brazil [9] Market Dynamics - Average realized gold prices increased to US$3,185 per ounce in Q2 2025, a 44% increase compared to Q2 2024 [19] - Average copper prices also saw a 5% increase, reaching US$4.46 per pound in Q2 2025 [19] Strategic Initiatives - Aura exercised options to acquire 100% ownership of the Pé Quente and Carajás projects, reinforcing its resource base [11] - The company invested in Altamira Gold Corp. through a private placement, acquiring additional shares to enhance its exploration potential [12]